Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 4Uterine Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Lymphatic Metastasis 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

Paclitaxel 28Carboplatin 28pembrolizumab 25Bevacizumab 14liposomal doxorubicin 12Cisplatin 11Gemcitabine 10Radiotherapy 8Drug Therapy 8Cyclophosphamide 8Blood Specimen Collection 8Topotecan 7Nivolumab 7olaparib 6Doxorubicin 6niraparib 5Therapeutics 5Dexamethasone 5pertuzumab 4pazopanib 4lenvatinib 4fludarabine 4cemiplimab 4atezolizumab 4Trastuzumab 4Surveys and Questionnaires 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Fulvestrant 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × TP protocol × Gynecologic × Clear all
NCT06532539 2026-04-24

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
30 enrolled
Gynecologic

Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡